Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.

JO, Pestana; JM, Grinyo; Y, Vanrenterghem; T, Becker; JM, Campistol; S, Florman; VD, Garcia; N, Kamar; P, Lang; RC, Manfro; P, Massari; MD, Rial; MA, Schnitzler; S, Vitko; T, Duan; A, Block; MB, Harler; A, Durrbach

doi:10.1111/j.1600-6143.2011.03914.x

Public

Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.

Shared by NobleBlocks on Feb 2, 2012 • 12:00 AM UTC

Authors:

Pestana JO

Grinyo JM

Vanrenterghem Y

Abstract

Recipients of extended-criteria donor (ECD) kidneys have poorer long-term outcomes compared to standard-criteria donor kidney recipients. We report 3-year outcomes from a randomized, phase III study in recipients of de novo ECD kidneys (n = 543) assigned (1:1:1) to either a more intensive (MI) or le...

Discussions